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ARTICLE OPEN
Rabies-based vaccine induces potent immune responses against
Nipah virus
Rohan Keshwara1, Thomas Shiels1, Elena Postnikova2, Drishya Kurup1, Christoph Wirblich1, Reed F. Johnson3 and Matthias J. Schnell1,4
Nipah Virus (NiV) is a re-emerging zoonotic pathogen in the genus Henipavirus of the Paramyxoviridae family of viruses. NiV is
endemic to Bangladesh and Malaysia and is highly fatal to both livestock and humans (human case fatality rate= 74.5%). Currently,
there is no approved vaccine against NiV on the market. The goal of this study was to use a recombinant RABV vector expressing
NiV glycoprotein (NiV G) to develop a bivalent candidate vaccine against NiV disease and rabies virus (RABV) disease, which is also a
signiﬁcant health burden in the regions where NiV is endemic. The rabies vector is a well-established vaccine strain that lacks
neurovirulence and can stably expresses foreign antigens that are immunogenic in various animal models. Mice inoculated
intranasally with the live recombinant RABV/NiV vaccine (NIPARAB) showed no signs of disease. To test the immunogenicity of the
vaccine candidate, groups of C57BL/6 mice were immunized intramuscularly with a single dose of live vaccine particles or two
doses of chemically inactivated viral particles. Both vaccination groups showed NiV G-speciﬁc seroconversion, and the inactivated
(INAC) vaccine group yielded higher titers of NiV G-speciﬁc antibodies. Furthermore, cross-reactivity of NiV G-speciﬁc immune sera
against Hendra virus (HeV), was conﬁrmed by immunoﬂuorescence (IF) and indirect ELISA against soluble recombinant HeV
glycoprotein (HeV G). Both live and killed vaccines induced neutralizing antibodies. These results indicate that NIPARAB may be
used as a killed virus vaccine to protect humans against NiV and RABV, and possibly as a preventative measure against HeV as well.
npj Vaccines            (2019) 4:15 ; https://doi.org/10.1038/s41541-019-0109-5
INTRODUCTION
Nipah disease is a highly fatal zoonotic disease whose causative
agent is Nipah virus, a negative sense RNA virus of the Henipavirus
genus within the Paramyxoviridae family. NiV was discovered in
1999 during an outbreak of encephalitis in Malaysia and was
identiﬁed and isolated after methods for Japanese Encephalitis
prevention were ineffective.1 This inaugural NiV outbreak caused
at least 265 cases of encephalitis and 105 deaths, and necessitated
the culling of over 1 million pigs, which were found to be
important for transmission to humans.1,2 Although no further
outbreaks in Malaysia have occurred, there have been 3 outbreaks
in India and nearly annual outbreaks in Bangladesh since 2001,
typically resulting from bat-to-human transmission via consump-
tion of contaminated raw date palm sap.3 An outbreak in May
2018 in the state of Kerala in India had a case fatality rate of 86%,
solidifying NiV as a persistent and grave threat in South Asia.4
Infections in fruit bats, the natural reservoir for the virus, seem
to be asymptomatic. However, pigs can suffer from respiratory
and neurological symptoms. Infection in humans is often highly
fatal, and clinical manifestation is characterized by fever, head-
ache, visual and motor skill dysfunction, acute respiratory illness,
and encephalitis.3 The NiV strains that cause human cases in
Bangladesh and India produce greater respiratory issues and more
instances of human-to-human transmission than outbreak strains
in Malaysia. As such, these cases are marked by higher mortality
rates, reﬂective of pathogenic differences between the strains, as
well as less developed healthcare infrastructure in the region.3
NiV attachment, fusion, and entry require coordinated effort
from two membrane-anchored envelope proteins for successful
infection. The glycoprotein (G) binds to ephrin-B2 and ephrin-B3
receptors on host target cells, and the fusion (F) protein is
responsible for driving fusion of apposing viral and cellular
membranes for entry.5,6 The ephrin-B2 and ephrin-B3 cellular
receptors are highly conserved between potential host species
(95–98% similar), including humans, horses, pigs, cats, dogs, and
ﬂying foxes, thus conﬁrming the ability of NiV to infect a wide
array of mammalian species.5 NiV G shows an afﬁnity for ephrin-B2
and ephrin-B3 receptors that is 30-times higher than the
glycoprotein of the closely related Hendra Virus (HeV), which
has been known to cause outbreaks with severe respiratory
disease in horses followed by transmission to humans.7 The strong
neurotropism of NiV could be explained by the fact that ephrin-B2
and ephrin-B3 are highly expressed in the nervous system.8
NiV is classiﬁed as biosafety level 4 (BSL4) pathogen and
considered to be a bioterrorism and agroterrorism threat.9 A safe
and effective vaccine against NiV for both humans and livestock
would be greatly beneﬁcial to prevent NiV disease in endemic
regions and to reduce the risk of NiV becoming a global danger.
Current work to establish a NiV vaccine has pursued various
promising approaches with, some of which are outlined here. A
live-attenuated recombinant measles virus (MV) expressing NiV G
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for human use (rMV-Ed-G) completely protected hamsters upon
lethal NiV challenge. In a follow-up study, two African green
monkeys (AGMs) immunized with 2 doses of rMV-Ed-G and
subsequently challenged had no clinical signs before euthana-
sia.10 MV-based vaccine vectors can confer long-lasting immu-
nity.11 Furthermore, preexisting immunity to MV in the human
population does not seem to confound successful vaccination
attempts.12,13 A VLP-based vaccine approach has also been tested
for efﬁcacy in a Syrian golden hamster challenge model. VLPs are
antigenically similar to parental virus and are generally more
immunogenic than subunit vaccines and can stimulate both
humoral and cellular arms of the immune system.14 While both
single and triple doses of VLPs expressing NiV G were able to fully
protect hamsters from challenge, adjuvant was required to boost
immunity and achieve high titers of neutralizing antibodies (nAbs).
Moreover, incomplete lethality in the model allowed for survival in
control groups not receiving vaccination, thereby complicating
the vaccine-speciﬁc effect on survival.15 Further testing in pre-
clinical models is warranted. A single administration of live-
attenuated replication-competent recombinant vesicular stomati-
tis virus (VSV) lacking its native glycoprotein but expressing both
Ebola GP and NiV G (rVSV-ZEBOV-GP-NiVG) was shown to prevent
virus shedding, replication, and Nipah disease in AGMs.16,17 While
live VSV-based vaccine vectors may have utility in emergency
situations or for ring vaccination, regulatory approval for use in
humans has been slow due to concerns regarding potential
pathogenesis.18,19 Widespread adverse events and questionable
efﬁcacy in human populations of rVSV-EBOV may represent
existing gaps in VSV-vectored vaccine approaches.20–22 However,
replication-defective single-cycle recombinant vesicular stomatitis
viruses (VSVΔG) pseudotyped with either NiV F or G showed
protection against 1000 times LD50 NiV challenge in Syrian golden
hamsters after a single dose inoculation, offering a distinct safety
advantage over the live-attenuated rVSV-ZEBOV-GP-NiVG.18 None-
theless, production requires multiple plasmid transfections which
can be costly for large-scale manufacturing.
In this study, we aimed to develop a RABV-based vaccine
against NiV for both animals and humans. Vaccines based on
RABV have been shown to induce strong humoral responses
against other pathogens and inactivated RABV vaccines are
considered remarkably safe.23–27
RESULTS
Rescue of NIPARAB in cell culture
The parental RABV vector used in this study, BNSP333, is derived
from the SAD B19 strain, which is a vaccine strain attenuated by
tissue culture passage.26 This vector was designed to contain an
additional RABV stop-start transcription signal sequence with unique
BsiWI and NheI restriction sites between the nucleoprotein (N) and
phosphoprotein (P) genes for the introduction of foreign genes.28 To
further increase the safety proﬁle of the vector, an arginine to
glutamic acid mutation was introduced at amino acid position 333
of RABV G, which greatly reduces neurovirulence.23,29,30
To develop full-length NIPARAB cDNA for use in recovery of the
recombinant virus, we inserted a codon-optimized version of NiV
G (Bangladesh strain) into the BNSP333 vector in between RABV N
and P genes. This cDNA serves as the antigenome template from
which single-stranded negative-sense RNA genomes are made.
During recovery, this construct was co-transfected into BSR cells
along with support plasmids individually bearing RABV genes
required for assembly, packaging, and budding of recombinant
virions, as previously described.31 For our studies, we generated
both a live version of the vaccine and a chemically inactivated
version using beta propiolactone which impedes virus replication
while maintaining antigenicity of target immunogens32 (Fig. 1a).
Expression of NiV G by NIPARAB
Successful antigenicity of NiV G and RABV G by our vaccine
depends on their expression at the surface of NIPARAB-infected
producer cells so that the host cell-derived envelopes of viral
progeny will contain both glycoproteins. To analyze co-expression,
VERO cells were either mock infected or infected with live
BNSP333 or NIPARAB at a multiplicity of infection (MOI) of 0.01 for
48 h before performing a surface immunoﬂuorescence assay
followed by confocal microscopy imaging. Cells were dual stained
with a human monoclonal antibody directed against RABV G and
either pooled polyclonal necropsy sera from mice immunized with
2 doses of INAC NIPARAB or one intranasal (i.n.) dose of live
recombinant VSV expressing Hendra G (rVSV-HeV-G). Hendra G-
speciﬁc sera was used with the knowledge of cross-reactivity to
identify NiV G expression in the absence of NiV G-speciﬁc sera.
Only NIPARAB-infected cells co-expressed RABV G and NiV G
(Fig. 1b), indicating that NIPARAB is a viable bivalent vaccine
vector.
Characterization of recombinant NIPARAB virions
To conﬁrm that RABV G and NiV G are both incorporated into
NIPARAB virions, we evaluated puriﬁed virions from several
different recombinant viruses by 10% SDS-PAGE and SYPRO Ruby
staining (Fig. 2). A prominent band with an apparent molecular
size slightly above 70 kDa was exclusively detected in lanes
containing INAC NIPARAB virions or soluble NiV G protein (Fig. 2).
These bands were consistent with the expected size of NiV G,33–35
and they migrated similarly but distinctly lower than HeV G
(~100 kDa) derived from virions of recombinant BNSP333 expres-
sing codon-optimized HeV G (HENDRARAB).7,36 NIPARAB virions
also incorporated all necessary RABV proteins as determined by
comparison to parental BNSP333 virions.
Puriﬁed virions were also assessed by Western blot and probed
with rabbit polyclonal HeV G antisera (Fig. 2b). Bands correspond-
ing to HeV G (~100 kDa) and NiV G (>70 kDa) were speciﬁcally
detected in lanes containing HENDRARAB and NIPARAB viral
particles, respectively. Furthermore, soluble recombinant NiV G
protein with transmembrane domain and N-terminal cytoplasmic
tail deletion was also detected with a slightly lower molecular size
than the full-length protein, as expected. This ﬁnding was
consistent with results from the stained protein gel and signiﬁed
that speciﬁc sera against HeV G could cross-react with NiV G. No
proteins were detected with negative control virions from parental
BNSP333 or recombinant BNSP333 expressing an unrelated
glycoprotein from Marburg virus (FILORAB3). These results
indicated that NiV G had successfully incorporated into the RABV
vaccine vector.
NiV G incorporation does not increase RABV vaccine pathogenicity
While incorporating NiV G into the RABV vector does not trigger
safety concerns in a killed vaccine, it could be an issue for use as a
live viral vector. NiV is neurotropic, since its envelope protein
binds to receptors predominantly expressed on neuronal cells,
and Nipah disease has been known to cause encephalitis and
neurological symptoms in infected humans.1,3 Therefore, live
NIPARAB inoculation could potentially lead to pathogenicity by
restoring neurovirulence, even though BNSP333 is nonvirulent
after peripheral administration in adult mice.23 To study this
potential impact, three groups of ten C56BL/6 mice (split equally
by gender) were infected i.n. with 5.75 log10 focus-forming units
(ffu) of either live BNSP333 (negative control), NIPARAB, or SPBN
(positive control). Animals were monitored for weight loss and
clinical signs of disease for 40 days to observe both immediate
and latent adverse effects. Endpoint criteria for euthanasia were
weight loss exceeding 20% of the original body weight or
hallmark neurological symptoms, such as ataxia. SPBN is derived
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from the same rabies virus vaccine strain as BNSP333, but it lacks
the attenuating mutation in RABV G, making it lethal when
administered i.n. to adult mice.23 All mice receiving SPBN
succumbed to infection by day 10 post-exposure, whereas all
mice inoculated with BNSP333 remained healthy with no weight
loss or malaise. Similarly, all mice infected with live NIPARAB
survived the duration of the study with no apparent pathogeni-
city, as indicated by steady weight gain and the absence of
neurological disease (Fig. 3a, b). These data demonstrate that
addition of NiV G to BNSP333 does not reestablish pathogenicity
in the parental vector within an immune competent mouse model
and may be safe for use as a wildlife vaccine.
Immunogenicity against NiV G
To analyze the humoral response to NiV G elicited by NIPARAB,
groups of ten C57BL/6 mice (5 males, 5 females) were
intramuscularly (i.m.) immunized with one dose (1E5 ffu) of live
or 2 doses (10 ug each) of either INAC NIPARAB or INAC BNSP333
(Fig. 4a). Sera were collected at days 14, 28, and 45 and analyzed
in an indirect ELISA using soluble NiV G as capture antigen to
quantitatively determine NiV G-speciﬁc antibody titers. As a
positive control in these assays, we included pooled antisera from
a group of mice immunized i.n. with live recombinant VSV
expressing codon-optimized HeV G, which was shown to be cross-
reactive toward NiV G in both Western blot (Fig. 2b) and IF
(Fig. 1b). Robust seroconversion was achieved as early as day 14
after a single vaccination in groups immunized with either live or
INAC NIPARAB but not in the control group receiving INAC
BNSP333 (Fig. 4b).
Approximately 2 weeks after completion of the prime-boost
immunization schedule (day 45), we characterized ﬁnal sera by
ELISA to analyze the persistence of the NiV G-speciﬁc humoral
response. Average EC50 values for each group were calculated
based on 4-parameter logistic regression curves for each animal.
All mice vaccinated with live or INAC NIPARAB elicited substan-
tially, higher titers of anti-NiV G antibodies compared with
BNSP333-vaccinated negative control animals, which displayed
background levels of reactivity (i.e., EC50 values were undeter-
mined) (Fig. 5a, Table 1). Furthermore, male and female mice
immunized with INAC NIPARAB had signiﬁcantly higher NiV
G-speciﬁc antibody titers than either male or female mice
receiving live NIPARAB (Fig. 5a, Table 1). All groups of mice
seroconverted toward RABV G, and both male and female animals
in the INAC NIPARAB group showed signiﬁcantly higher titers of
RABV G-speciﬁc antibodies that either male or female animals
from both the negative control and live NIPARAB groups (Fig. 5b,
Table 2).
From previous studies in our lab with RABV-vectored vaccines
against hemorrhagic fever viruses, we discovered that antibody
quality informs survival and that a Th1-biased humoral response is
beneﬁcial for controlling infection after lethal challenge.37,38 In
C57BL/6 mice, skewing toward production of IgG2c antibodies is
indicative of a Th1-type response whereas generation of IgG1
antibodies suggest a Th2-type immunity. We assessed relative
titers of IgG2c and IgG1 antibodies in NiV G-speciﬁc sera from
animals immunized with either live or INAC NIPARAB by isotype
ELISA. Whereas there was no signiﬁcant difference (p > 0.05) in
titers of IgG2c vs. IgG1 antibodies in either male or female mice
receiving live NIPARAB, both male and female mice receiving INAC
NIPARAB had signiﬁcantly higher titers of IgG2c vs. IgG1 (Fig. 5c,
Table 3). Moreover, INAC NIPARAB mice had signiﬁcantly higher
titers of IgG2c (but not IgG1) antibodies compared to the live
vaccine group, regardless of gender (Fig. 5c, Table 3).
Vaccine-induced NiV G neutralizing antibody titers
Neutralizing antibodies (nAbs) are a correlate of protection against
many enveloped viruses including RABV, respiratory syncytial virus,
and dengue fever virus.39–41 To evaluate the capacity of antibodies
elicited by the NIPARAB vaccine to neutralize NiV, we employed an
in vitro ﬂuorescence reduction neutralization assay 50 (FRNA50).15
FRNA50 was performed as described in Materials and Methods. (Fig.
6, gray bars). HeV-speciﬁc sera effectively neutralized NiV, hence
demonstrating that HeV (G-speciﬁc) antibodies not only bind to NiV
G but also possess antiviral effector function. No neutralization was
observed in sera from negative control mice immunized with INAC
BNSP333, which is expected since these mice did not have any NiV
G-speciﬁc antibody titers in ELISA (Fig. 6, Group 1). However, sera
from all mice immunized with INAC NIPARAB developed nAbs,
Fig. 1 Vaccine constructs. a Schematic representation of recombinant rabies virus (attenuated SAD B19 vaccine strain) genome expressing
codon-optimized Nipah virus glycoprotein gene (Bangladesh strain) in between the nucleoprotein (N) and phosphoprotein (P) genes of
rabies. An asterisk indicates the Arg→Glu mutation in amino acid position 333 of RABV G that attenuates neurovirulence. Parental vector with
no foreign gene insertion, used as a negative control in immunogenicity and pathogenicity studies, is also depicted. b Confocal microscopy
image of VERO E6 cells that were ether mock infected or infected at an MOI of 0.01 for 48 h with live NIPARAB or BNSP333 before ﬁxing and
dual staining with a human monoclonal antibody directed against RABV G (green) and either polyclonal sera from mice immunized with INAC
NIPARAB (pooled sera 45 days post-infection (dpi) from mice receiving 2 doses of 10ug each) or live rVSV-HeV-G (pooled sera 57 dpi from mice
receiving one i.n. dose of 1E5 pfu) (red). Scale bars represent 24 µm
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although titers were variable between individual animals (Fig. 6,
Group 3). Similarly, mice vaccinated with live NIPARAB generated
NiV G-speciﬁc nAbs, except for 2 male animals for which no nAb
titers were detected (Fig. 6, Group 2). On account of these two
animals, there were signiﬁcant differences in nAb titers between live
NIPARAB-immunized males and corresponding females (*p < 0.05),
as well as when compared with both males and females immunized
with INAC NIPARAB (*p < 0.05). Overall, animals in the INAC NIPARAB
cohort had signiﬁcantly higher titers of nAbs than animals in the
corresponding live vaccine group (***p < 0.001). These results
suggest that neutralization may be an important component of
vaccine-induced protection by NIPARAB and that 2 doses of the
killed vaccine are more immunogenic than inoculation with live
vaccine regarding generation of NiV-speciﬁc nAbs. However, a
challenge study in animals vaccinated with NIPARAB needs to be
conducted to determine if nAbs correlate with survival.
DISCUSSION
Nipah virus is one of eight viruses designated by the World Health
Organization (WHO) as a priority pathogen due to its potential to
cause an international epidemic in the absence of effective drugs
or vaccines.42 Although outbreaks have been sporadic, mortality
rates in humans have been high (40 to 75%).1,3 Furthermore, there
is a signiﬁcant economic burden to pig farmers in endemic
regions whose livestock must be culled in response to an
outbreak.43 We have described the development of a killed
recombinant rabies-vectored NiV vaccine, NIPARAB, for eventual
use in humans to prevent NiV disease. We have also characterized
a live attenuated NIPARAB vaccine to be considered for use in
wildlife to curb transmission from the natural reservoir (pteropid
bats) to secondary reservoirs (e.g., pigs) and diminish spillover
events to humans.
Based on studies in African green monkeys (AGMs) comparing
the pathogenic differences between the Malaysian (NiVM) and
Bangladesh (NiVB) strains of NiV under identical experimental
conditions, we decided to choose NiVB as the immunogen in our
candidate NIPARAB vaccine. NiVB caused 100% mortality in
infected AGMs while NiVM caused only 50% mortality. Further-
more, histopathology in NiVB-infected AGMs showed more severe
lung and spleen phenotypes and a shorter therapeutic window for
human monoclonal antibody treatment than NiVM-infected
counterparts.44 Since there is a 95% amino acid sequence
homology between the glycoproteins of these two strains,19 an
effective vaccine against the more highly pathogenic NiVB strain
would likely protect against exposure to NiVM. In fact, this has
been demonstrated experimentally: ferrets vaccinated with a live
attenuated vesicular stomatitis virus (VSV) vaccine expressing NiV
G from the Bangladesh strain were 100% protected against
heterologous challenge with a Malaysian isolate of NiV.45 Studies
have also successfully utilized the F protein of NiV to develop
protective vaccines against both strains and HeV,15,19 but we
decided to target the glycoprotein to block virion-receptor
binding, an entry step that occurs before membrane fusion.
Our results indicated that both live and inactivated NIPARAB
elicited strong humoral immunity in mice, characterized by high
titers of antibodies against NiV G (Fig. 5a) and induction of
potently neutralizing antibodies against wildtype Malaysian NiV
strain (Fig. 6). Antibodies generated by INAC NIPARAB were mainly
of IgG2c isotype, suggesting a Th1-biased response. In antiviral
defense, Th1-type antibodies are known to participate in non-
neutralizing effector functions, such as NK cell-mediated antibody
dependent cytotoxicity (ADCC) or macrophage/monocyte-
mediated antibody dependent cellular phagocytosis (ADCP).46–49
It is possible that these other mechanisms contribute to vaccine-
induced protection with INAC NIPARAB in addition to classic
neutralization.
INAC NIPARAB offers several advantages over other NiV vaccines
currently under development. Since our candidate vaccine for
humans is chemically killed, viral replication is completely abrogated,
rendering our vaccine potentially safer than NiV vaccines that use a
live vector (e.g., live-attenuated rVSV-ZEBOV-GP-NiVMG), especially in
susceptible populations like immunocompromised individuals,
pregnant women, or children. A live virus vaccine might be better
intended for use in wildlife. Indeed, the rabies strain upon which our
recombinant NIPARAB is based (SAD B19) has been successfully used
Fig. 2 Analysis of puriﬁed virions of vaccine vectors. a Puriﬁed inactivated virions were loaded onto a 10% SDS-PAGE gel (4 μg per construct)
and stained with SYPRO Ruby to visualize incorporated proteins. Critical RABV proteins as well as foreign glycoproteins are indicated. Soluble
codon-optimized NiV G (0.5 μg) with transmembrane and cytoplasmic domain deletion (used for antibody capture in ELISAs) was loaded onto
right-most lane for visualization. b Conﬁrmation of NiV G incorporation into puriﬁed NIPARAB virions by Western blot analysis. 4 μg of puriﬁed
inactivated NIPARAB or control virions were loaded onto 10%SDS-PAGE gel and transferred to a nitrocellulose membrane. The blot was
probed with polyclonal rabbit anti-HeV G sera to identify NiV by cross-reactivity. Soluble codon-optimized NiV G (0.25 μg) with
transmembrane and cytoplasmic domain deletion (used for antibody capture in ELISAs) was loaded onto right-most lane for visualization
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as a live oral vaccine for wildlife in Europe.50 Our data have shown
that live NIPARAB does not cause pathogenicity in mice, even when
administered at a high dose (5.75log10 ffu) intranasally, and has the
added beneﬁt of bivalency toward rabies, a devastating pathogen
that widely affects both humans and wildlife in the same geographic
regions where NiV outbreaks occur. Moreover, INAC NIPARAB is
immunogenic after a single dose of unadjuvanted vaccine (Fig. 4b),
and titers remain elevated even one month after secondary
unadjuvanted immunization. By contrast, soluble NiV and HeV
glycoprotein subunit and VLP-based vaccines require one or more
doses of adjuvant to be immunogenic.15,19 Furthermore, INAC
NIPARAB does not have to contend with the issue of pre-existing
vector immunity in human cohorts like measles-vectored NiV
vaccines.12 Previous studies have shown additive immunity with
subsequent vaccinations of rabies-vectored inactivated
vaccines.7,37,38,51
The studies described here demonstrate the potential for a RABV
platform for the development of a safe and effective NiV vaccine.
Future studies will test NIPARAB protection in an animal model
susceptible to NiV, such as Syrian golden hamsters, and will also
establish the minimum protective dose and capacity to reduce NiV
disease severity and/or mortality. Furthermore, protection against
HeV challenge will be assessed since there is wide evidence for sera
cross reactivity between these two henipaviruses.52–54
METHODS
cDNA construction of vaccine vectors
We inserted codon-optimized Nipah virus glycoprotein gene G (Bangla-
desh strain, GenBank: AY988601.1) between the N and P genes of the
parental BNSP333 rabies vector using BsiWI and NheI restriction sites(16).
Codon bias optimization for human codon use was carried out by
GenScript Inc. The resulting plasmid was designated BNSP333-coNiV-G
(NIPARAB), and the correct sequence of the plasmid was conﬁrmed by
sequencing using primers targeting the region between the N and
P genes.
Fig. 3 Pathogenicity of live NIPARAB vaccine in male and female B6 mice. a Groups of ten 6-week-old to 8-week-old C57BL/6 mice (5 males
and 5 females per group) were intranasally (i.n.) infected with 5.6E5 ffu of live recombinant viruses: NIPARAB, BNSP333 (negative control), or
SPBN (positive control). Mice were weighed daily and monitored for signs of disease until day 40 post-inoculation. Endpoint criteria for
euthanasia were reached when mice lost more than 20% of their original body weight or displayed symptoms of disease. Weight curves are
reported as percentage lost or gained over time from the baseline weight. b Survival curve of C57BL/6 mice in this study. The log-rank
(Mantel-Cox) test was used for comparison of survival curves to assess signiﬁcant differences in survival
R. Keshwara et al.
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Recovery of recombinant vectors
X-tremeGENE 9 transfection reagent (Roche Diagnostics) in Opti-MEM was
used to transfect full-length viral cDNA clones along with support plasmids
bearing RABV N, P, G, and L genes under the control of a T7 promoter and
a plasmid expressing T7 RNA polymerase into BSR cells on 6-well plates as
described previously.31 Successful recovery was determined by a rabies
focus-forming assay. Brieﬂy, seven days after transfection, supernatant
from each transfected well of the 6-well plate was transferred to duplicate
wells of a 12-well plate seeded with VERO cells. Forty-eight hours later,
cells in the 12-well plate were ﬁxed with 80% acetone and stained with a
FITC-conjugated antibody against RABV N (Fujirebio Diagnostics, Inc).
Fluorescence microscopy was used to observe the appearance of viral foci,
indicative of recovered, infectious recombinant RABV.
Sucrose puriﬁcation and inactivation of virus particles
NIPARAB was grown large-scale by infecting VERO cells in a 2-stack plate at
MOI= 0.001. The supernatant was collected every 4 days for 6 harvests.
Harvests were titered using rabies focus-forming assay55 and harvest 4–6
were pooled and concentrated 9× in a stirred 300-ml ultraﬁltration cell
(Millipore). Concentrated supernatant was then centrifuged for 2 h at
76,755×g through a 20% sucrose cushion using SW32 Ti rotor (Beckman,
Inc.) to pellet virus particles. Virion pellets were resuspended in phosphate-
buffered saline (PBS), and protein concentrations were determined using a
bicinchoninic acid (BCA) assay kit (Pierce). The virus particles were
chemically inactivated with β-propiolactone (BPL) at a dilution of 1:2000
overnight at 4 °C. BPL in the virus preparation was inactivated the next day
by hydrolysis at 37 °C for 30min. The absence of infectious particles was
veriﬁed by inoculating VERO cells in a T25 vessel with 10 μg of BPL-
inactivated virus for two passages. Inoculated cells were ﬁxed and stained
with FITC-conjugated anti-RABV N mAb and visualized by ﬂuorescence
microscopy for the presence of foci of infection.
Immunoﬂuorescence testing of the vaccine
VERO cells were plated onto 12 well plates with 3E5 cells with 15mm
circular diameter coverslips inserted and then incubated overnight at
37 °C. The next day the wells were infected at an MOI of 0.01 in 500 μL of
serum-free media (OptiPro) per well with NIPARAB or BNSP333-cover-G
mixed by rocking and then stored at 34 °C for 48 h. After 48 h, cells were
washed with 1mL of 1× PBS, then ﬁxed with 500 μL of 2% paraformalde-
hyde (PFA) diluted in PBS for 15min at room temperature. PFA was
Fig. 5 Analysis of terminal sera from NIPARAB immunized mice. a, b Average EC50 values (bars) were derived from ELISA curves measuring
either total NiV G IgG (left panel) or RABV G (middle panel) from individual mice (open circles) from each vaccination group. Statistical
signiﬁcance was performed using 2-way ANOVA followed by uncorrected Fisher’s LSD to compare immunization groups (*p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001). c IgG1 and IgG2 isotype responses in ﬁnal sera (day 45) from live or inactivated NIPARAB-immunized mice were
assessed by ELISA at day 45 and average EC50 values (bars) were determined based on individual ELISA curves (open circles). Statistical
signiﬁcance was performed using 3-way ANOVA followed by uncorrected Fisher’s LSD test to compare immunization groups (*p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001). Error bars represent standard deviation from the mean of three replicate values
Fig. 4 Primary humoral responses to NiV G in murine model of
NIPARAB immunization. a Experimental timeline for immunization of
C57BL/6 mice (n = 10, 5 males and 5 females per group). C56BL/6
mice were immunized with 1 dose of 105 ffu live virus (Day 0) or 2
doses of 10 μg inactivated virus (Days 0 and 28). Sera were collected
on days 14 and 45 and analyzed by ELISA to determine humoral
response. b ELISA of the primary NiV G speciﬁc responses in pooled
sera from either male or female mice in each vaccination group,
14 days after the initial immunization (prime). Error bars represent
standard deviation from the mean of three replicate values
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removed by aspiration and cells washed 3× with 1× PBS. 1 mL of blocking
solution (4% fetal bovine serum [FBS] in PBS) was added to each well for
1 h at room temperature while on the shaker. Blocking solution was
aspirated off, then 500 μL of dual primary stain (1:250 dilution of anti-RABV
G human mAb 4C12 at 4 mg/mL (Dr. Scott Dessain, Lankenau Institute for
Medical Research, Wynnewood, PA) plus 1:200 dilution of mouse sera) in
2% FBS was added for 1 h while rocking. Cells were washed four times with
1× PBS and then incubated with 500 μL of a 1:250 dilution of both anti-
mouse Cy3 (Jackson ImmunoResearch) and anti-human Cy2 (Jackson
ImmunoResearch) secondary antibodies containing Cy2 and Cy3 dyes and
incubated at room temperature for 45min. Cells were washed 5 times with
1× PBS and then cells were mounted onto slides with the mounting
solution containing DAPI (Abcam) with the coverslips face down onto the
slide and stored overnight at room temperature for visualization by
confocal microscopy the following day.
Virus characterization
Sucrose-puriﬁed virus particles were denatured with urea buffer (125mM
Tris-HCl [pH 6.8], 8 M urea, 4% sodium dodecyl sulfate, 5%
β-mercaptoethanol, 0.02% bromophenol blue, Thermo Fisher Scientiﬁc)
at 95 °C for 5 min. Stained protein gel: 8 μg of particles were resolved by
10% SDS–PAGE and thereafter stained overnight with SYPRO Ruby for total
protein analysis. Western blot: 4 μg of particles were resolved on a 10%
SDS-PAGE gel and transferred onto a nitrocellulose membrane in Towbin
buffer (192mM glycine, 25 mm Tris, 20% methanol, Thermo Fisher
Scientiﬁc) for Western blot analysis. The nitrocellulose membrane was
Table 1. Anti-Nipah G IgG responses
Multiple comparisons: uncorrected Fisher’s LSD Summary Individual P value
Male:INAC NIPARAB vs. Male:LIVE NIPARAB *** 0.0009
Male:INAC NIPARAB vs. Male:INAC BNSP333 **** <0.0001
Male:INAC NIPARAB vs. Females:LIVE NIPARAB ** 0.0031
Male:INAC NIPARAB vs. Females:INAC BNSP333 **** <0.0001
Male:LIVE NIPARAB vs. Females:INAC NIPARAB **** <0.0001
Male:INAC BNSP333 vs. Females:INAC NIPARAB **** <0.0001
Male:INAC BNSP333 vs. Females:LIVE NIPARAB * 0.036
Females:INAC NIPARAB vs. Females:LIVE NIPARAB **** <0.0001
Females:INAC NIPARAB vs. Females:INAC BNSP333 **** <0.0001
Females:LIVE NIPARAB vs. Females:INAC BNSP333 * 0.0361
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Table 2. Anti-rabies G IgG responses
Multiple comparisons: uncorrected Fisher’s LSD Summary Individual P value
Male:INAC NIPARAB vs. Male:LIVE NIPARAB * 0.031
Male:INAC NIPARAB vs. Male:INAC BNSP333 * 0.0423
Male:LIVE NIPARAB vs. Females:INAC NIPARAB ** 0.0024
Male:INAC BNSP333 vs. Females:INAC NIPARAB ** 0.0035
*p < 0.05, **p < 0.01
Table 3. Anti-Nipah G IgG isotype responses
Multiple comparisons: uncorrected Fisher’s LSD Summary Individual P value
IgG1:Male INAC NIPARAB vs. IgG2c:Male INAC NIPARAB *** 0.0002
IgG1:Male INAC NIPARAB vs. IgG2c:Females INAC NIPARAB **** <0.0001
IgG1:Females INAC NIPARAB vs. IgG2c:Male INAC NIPARAB ** 0.0016
IgG1:Females INAC NIPARAB vs. IgG2c:Females INAC NIPARAB **** <0.0001
IgG1:Male LIVE NIPARAB vs. IgG2c:Male INAC NIPARAB **** <0.0001
IgG1:Male LIVE NIPARAB vs. IgG2c:Females INAC NIPARAB **** <0.0001
IgG1:Females LIVE NIPARAB vs. IgG2c:Male INAC NIPARAB **** <0.0001
IgG1:Females LIVE NIPARAB vs. IgG2c:Females INAC NIPARAB **** <0.0001
IgG2c:Male INAC NIPARAB vs. IgG2c:Male LIVE NIPARAB **** <0.0001
IgG2c:Male INAC NIPARAB vs. IgG2c:Females LIVE NIPARAB *** 0.0002
IgG2c:Females INAC NIPARAB vs. IgG2c:Male LIVE NIPARAB **** <0.0001
IgG2c:Females INAC NIPARAB vs. IgG2c:Females LIVE NIPARAB **** <0.0001
**p < 0.01, ***p < 0.001, ****p < 0.0001
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then blocked in TBST (100mM Tris-HCl [pH 7.9], 150mM NaCl, 0.05%
Tween 20, Thermo Fisher Scientiﬁc) containing 5% dried milk (Millipor-
eSigma) at room temperature for 1 h. After blocking, the membrane was
incubated overnight with rabbit polyclonal HeV G antisera (Dr. Christopher
Broder, Uniformed Services University, Bethesda, MD) at a dilution of
1:1000 in antibody diluent (1% bovine serum albumin (BSA) in PBS with
0.1% Tween-20). After washing, the blot was incubated for 1 h with donkey
anti-rabbit IgG conjugated to horseradish peroxidase (HRP) at a 1:20,000 in
antibody diluent. Bands were developed with SuperSignal West Dura
Chemiluminescent substrate (Pierce). The SDS-PAGE gel and correspond-
ing Western blot in Fig. 4 derived from the same experiment and were
processed in parallel.
Pathogenicity and immunogenicity studies
(i) Animal ethics statement. This study was carried out in strict adherence
to recommendations described in the Guide for the Care and Use of
Laboratory Animals,56 as well as guidelines of the National Institutes of
Health, the Ofﬁce of Animal Welfare, and the United States Department of
Agriculture. All animal work was approved by the Institutional Animal Care
and Use Committee (IACUC) at Thomas Jefferson University (animal
protocols 00990 and 01526). All procedures were carried out under
isoﬂurane anesthesia by trained personnel, under the supervision of
veterinary staff. Mice were housed in cages, in groups of 5, under
controlled conditions of humidity, temperature, and light (12-h light/12-h
dark cycles). Food and water were available ad libitum.
(ii) Immunizations. Three groups of 6-week-old to 8-week-old C56BL/6
mice were immunized intramuscularly with 10 μg of virus particles in a
total volume of 100 μL (50 μL per hindlimb). The three groups were as
follows: inactivated NIPARAB, live NIPARAB, and inactivated BNSP333. Each
group consisted of 5 male and 5 female mice. Mice receiving inactivated
vaccine were given two doses, once on day 0 and once on day 28, while
mice receiving the live NIPARAB vaccine were only immunized once,
on day 0.
(iii) Pathogenicity experiments. Three groups of 6-week-old to 8-week-old
C56BL/6 mice were intranasally infected with 10 μL of 5.6 × 105 ffu of live
virus (SPBN, BNSP333, or NIPARAB). Each group consisted of 5 male and 5
female mice. The mice were monitored for signs of disease such as rufﬂed
fur, ataxia, and disorientation and weighed until day 40. Mice that lost
more than 20% of their original weight were considered to have reached
the endpoint and were euthanized.
Production of HA-tagged NiV G
Subconﬂuent T175 ﬂasks of 293 T cells (human kidney cell line) were
transfected with a eukaryotic expression vector (pDisplay) encoding amino
acids 71 to 602 of the head and stalk domains of codon-optimized NiV G
(Bangladesh strain) fused to an N-terminal hemagglutinin (HA) peptide.
Supernatant was collected 48 h after transfection, clariﬁed by centrifuga-
tion, and ﬁltered through a 0.45 μm ﬁlter before being loaded onto an
equilibrated anti-HA agarose column (Pierce) containing a 2.5 ml agarose
bed volume. The supernatant was allowed to bind to the column overnight
at 4 °C. The next day, the column was washed with 10-bed volumes of TBST
(TBS with 0.05% Tween 20) and 2-bed volumes of TBS, and bound HA-
coNiV-G was eluted with 5ml of 250 μg/ml HA peptide in TBS. Fractions
were collected and analyzed for the presence of HA-coNiV-G by western
blotting with monoclonal anti-HA antibody (Sigma) prepared in 5% BSA-
TBST. Peak fractions were pooled and dialyzed against PBS in 10,000
molecular weight cutoff dialysis cassettes (MWCO) (Thermo Scientiﬁc) to
remove excess HA peptide. After dialysis, the protein was quantiﬁed by
BCA and frozen in aliquots at −80 °C.
RABV and NiV G responses by ELISA
Sera from immunized mice were collected by retro-orbital eye bleed under
isoﬂurane anesthesia on days 0, 14, and 45, and samples were tested for
immunogenicity by indirect ELISA using N-terminus HA-tagged soluble
recombinant protein for antibody capture. We tested individual mouse
sera, as well as pooled sera for the presence of total IgG speciﬁc to NiV G
and RABV G. To test for anti-NiV G humoral responses, we produced
soluble NiV G (sNiV-G) as described above. sNiV-G was diluted in coating
buffer (50 mM Na2CO3 [pH 9.6]) at a concentration of 500 ng/mL and then
plated in 96-well ELISA MaxiSorp plates (Nunc) at 100 μL in each well.
RABV-G was also resuspended in coating buffer at a concentration of
500 ng/mL and then plated in 96-well ELISA MaxiSorp plates (Nunc) at
100 μl per well. After overnight incubation at 4 °C, plates were washed
three times with PBST (0.05% Tween 20 in 1× PBS) and incubated for 1 h at
room temperature with blocking buffer (5% dry milk powder in 1× PBST) in
a volume of 250 μl per well. The plates were then washed three times with
PBST and incubated overnight at 4 °C with 3-fold or 4-fold serial dilutions
of sera from immunized mice in PBS containing 0.5% BSA. Plates were
washed 3 times the next day, followed by the addition of horseradish
peroxidase-conjugated goat anti-mouse-IgG (H+ L) secondary antibody
(1:10,000) (Jackson ImmunoResearch). After incubation for 2 h at room
temperature, plates were washed 3 times with PBST, and 200 μl of o-
phenylenediamine dihydrochloride (OPD) substrate (Sigma) was added to
each well. The reaction was stopped by the addition of 50 μl of 3 M H2SO4
per well after 15min. Optical density was determined at 490 nm (OD490).
Fluorescence reduction neutralization assay (FRNA50)
FRNA50 was used to determine the highest serum dilution, which would
reduce the infectivity of the virus by 50%. This assay (with minor
modiﬁcations) was described in Walpita et al., 2017 (ref.14). Brieﬂy, VERO E6
cells were seeded at 40,000 cells/well at 1 day prior to the experiment.
Serum samples were heat inactivated for 60min at 56 °C and serially
diluted in serum-free DMEM. After incubation, diluted samples were mixed
with 4000 PFU of NiV and incubated for 1 h at 37 °C. Serum-virus mixtures
were added to cells’ monolayers and incubated at 37 °C/5% CO2 for 48 h
before ﬁxing with 10% NBF for 24 h. Immunoﬂuorescence assay (IFA) was
performed by permeabilizing of cells with 0.25% Triton X-100 in PBS for
5 min, blocking with 3% BSA for 30min, staining with a NiV G protein-
speciﬁc rabbit polyclonal antiserum (produced by ThermoFisher Scientiﬁc
from NiV GP “293 FreeStyle Tet-NiV-sG”, a gift from Dr. Christopher C.
Broder, Uniformed Services University) in 3% BSA diluted at 1:2000 at 37 °C
for 60min. In the ﬁnal step of IFA, goat anti-rabbit IgG (H+ L) secondary
antibody, Alexa Fluor® 594 conjugate (Life Technologies), and Hoechst
33342 nucleic acid stain (ThermoFisher Scientiﬁc) were applied to the cells
for 30min at room temperature (1:2500 dilution each). Cells were washed
with 1× PBS between each step, except for “blocking-primary antibody
step”. The percentage of cells infected with NiV was detected using High
Content Imaging System Operetta (PerkinElmer).
Reporting Summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
Fig. 6 Vaccine-induced neutralization titers in vitro. Sera from mice
in our immunization study (n= 10 per group) were analyzed in a
Fluorescence Reduction Neutralization Assay 50 (FRNA50) with one
FRNA50 value per animal. Y-axis gives the antibody dilution required
to reduce infectivity by 50%. Both NiV G and HeV G rabbit polyclonal
antisera were used as positive controls (gray bars). Statistical
signiﬁcance between groups was performed using ordinary one-
way ANOVA followed by uncorrected Fisher’s LSD test to compare
immunization groups. Non-parametric Kruskal-Wallis test followed
by uncorrected Dunn’s multiple comparisons test was used to
compare statistical signiﬁcance based on gender (*p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001)
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